Literature DB >> 16825115

Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas.

Lucio Agozzino1, Franca Ferraraccio, Marina Accardo, Salvatore Esposito, Manuela Agozzino, Luigi Cuccurullo.   

Abstract

Craniopharyngioma is a slow-growing epithelial tumor with an unpredictable tendency to recur. To verify the reliability in predicting the clinical outcome, some morphological and immunohistochemical findings were analyzed in 37 primitive tumors and in 6 recurrences (one recurred twice). All the tumors were surgically excised and all recurrences exhibited an adamantinomatous pattern; mitotic rate was low (< 5 x 10 HPF) in both recurrent and in nonrecurrent tumors. Primary tumors showed a mean positivity of 1.7% (range 0.3-2%) to PCNA vs. 4.1% (range 0.3-8%) in recurrences. The MIB-1 Labelling Index was: 22.12% in primary tumors, 27.5% in recurrences, 31.3% in adult nonrecurrent tumors, and 4.1% in the pediatric tumor. CD34 labeling vessels/field was 9.3 in primary tumors and 9.91 in the recurrences; VEGF expression was higher in recurrences than in primary tumors (40 vs. 25%). Ultrastructural analysis showed fenestrated endothelium with hydropic changes in VEGF-positive vessels. Lack of clear correlations between morphological or immuno-staining patterns and behavior suggests that these features have no prognostic value in adult as well as in pediatric craniopharyngiomas. In this study, the only results that may be related to the aggressiveness of tumor is the major vascularization in the recurrent tumors in which the vessels show also ultrastructural changes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825115     DOI: 10.1080/01913120500408018

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  7 in total

1.  Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma.

Authors:  Zhiqiang Xia; Wenqing Liu; Shengdong Li; Ge Jia; Yuqi Zhang; Chunde Li; Zhenyu Ma; Jihui Tian; Jian Gong
Journal:  Neurochem Res       Date:  2011-08-04       Impact factor: 3.996

2.  Single and hypofractionated stereotactic radiotherapy with CyberKnife for craniopharyngioma.

Authors:  Hiromitsu Iwata; Koshi Tatewaki; Mitsuhiro Inoue; Naoki Yokota; Yoshimi Baba; Ryutaro Nomura; Yuta Shibamoto; Kengo Sato
Journal:  J Neurooncol       Date:  2011-08-23       Impact factor: 4.130

Review 3.  Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Authors:  Josephine R Coury; Brittany N Davis; Christoforos P Koumas; Giovanna S Manzano; Amir R Dehdashti
Journal:  Neurosurg Rev       Date:  2018-04-17       Impact factor: 3.042

Review 4.  A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma.

Authors:  Aaron J Clark; Tene A Cage; Derick Aranda; Andrew T Parsa; Peter P Sun; Kurtis I Auguste; Nalin Gupta
Journal:  Childs Nerv Syst       Date:  2012-10-23       Impact factor: 1.475

5.  Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma.

Authors:  Michael E Sughrue; Isaac Yang; Ari J Kane; Shanna Fang; Aaron J Clark; Derrick Aranda; Igor J Barani; Andrew T Parsa
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

6.  Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology.

Authors:  Annett Hölsken; Marc Schwarz; Clarissa Gillmann; Christina Pfister; Michael Uder; Arnd Doerfler; Michael Buchfelder; Sven Schlaffer; Rudolf Fahlbusch; Rolf Buslei; Tobias Bäuerle
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

7.  Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population.

Authors:  Elżbieta Moszczyńska; Monika Prokop-Piotrkowska; Agnieszka Bogusz-Wójcik; Wiesława Grajkowska; Sylwia Szymańska; Mieczysław Szalecki
Journal:  Childs Nerv Syst       Date:  2020-02-07       Impact factor: 1.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.